Consensus Amgen Inc.

Equities

AMGN

US0311621009

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 13/02/2026 GMT			5-day change	1st Jan Change
369.19 ^USD	+1.52%		-3.94%	+12.80%

02-12	Amgen Inc. Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium, Feb-12-2026 05:00 PM
02-12	European Commission approves Amgen's Uplizna® for generalized myasthenia gravis	RE

Evolution of the Average Target: Amgen Inc.

Evolution of the Target Price: Amgen Inc.

Changes in Analyst Recommendations: Amgen Inc.

72c51dc42c13b14f583486e9e99.eqedlN6_B6J0Hxiv4JQ19JFXBmd9zZW6luuCB5RNxMA.NvHV0qnsN8sfZ3rdmq1lm8BlZ1UYuqb_9YPqSvY9i40849jT7ox-wB5Kfw~6b3bb2f7d3a78aaa7df9e84f8aeaf002

Analysts' recommendations: Amgen Inc.

02-10	Mizuho Raises Price Target on Amgen to $295 From $280, Keeps Outperform Rating	MT
02-06	Argus Research Adjusts Price Target on Amgen to $400 From $360, Maintains Buy Rating	MT
02-04	TD Cowen Adjusts Price Target on Amgen to $420 From $389, Maintains Buy Rating	MT
02-04	Leerink Partners Adjusts Price Target on Amgen to $355 From $305, Maintains Market Perform Rating	MT
02-04	RBC Raises Price Target on Amgen to $360 From $335, Keeps Outperform Rating	MT
02-04	Morgan Stanley Raises Price Target on Amgen to $309 From $304, Keeps Equalweight Rating	MT
01-29	Oppenheimer Adjusts Price Target on Amgen to $400 From $380, Maintains Outperform Rating	MT
01-29	Oppenheimer Raises Price Target on Amgen to $400 From $380, Keeps Outperform Rating	MT
01-26	UBS Adjusts Price Target on Amgen to $390 From $380, Maintains Buy Rating	MT
01-23	Bernstein Downgrades Amgen to Market Perform From Outperform, Price Target is $335	MT
01-07	UBS Upgrades Amgen to Buy From Neutral, Raises Price Target to $380 From $317	MT
12-10	Wells Fargo Adjusts Price Target on Amgen to $325 From $300, Maintains Equalweight Rating	MT
12-10	HSBC Adjusts Price Target on Amgen to $425 From $381, Maintains Buy Rating	MT
12-03	BMO Capital Adjusts Price Target on Amgen to $372 From $335, Maintains Outperform Rating	MT
12-02	Janux dives as gaps in prostate cancer study data worry investors	RE
11-19	HSBC Adjusts Price Target on Amgen to $381 From $343, Maintains Buy Rating	MT
11-18	Daiwa Securities Adjusts Price Target on Amgen to $370 From $310, Maintains Outperform Rating	MT
11-13	Scotiabank Initiates Amgen at Sector Outperform With $385 Price Target	MT
11-11	Deutsche Bank Adjusts Amgen Price Target to $285 From $280, Maintains Hold Rating	MT
11-10	DZ Bank Adjusts Price Target on Amgen to $364 From $335	MT
11-06	Cantor Fitzgerald Adjusts Price Target on Amgen to $315 From $305, Maintains Neutral Rating	MT
11-06	Guggenheim Adjusts Price Target on Amgen to $305 From $288, Maintains Neutral Rating	MT
11-05	Goldman Sachs Adjusts Price Target on Amgen to $400 From $405, Maintains Buy Rating	MT
11-05	Morgan Stanley Adjusts Price Target on Amgen to $329 From $333, Maintains Equalweight Rating	MT
11-05	Wells Fargo Adjusts Amgen Price Target to $300 From $280, Maintains Equal Weight Rating	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

369.19USD

Average target price

345.56USD

Spread / Average Target

-6.40%

High Price Target

425.00USD

Spread / Highest target

+15.12%

Low Price Target

180.00USD

Spread / Lowest Target

-51.24%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Mizuho Securities
Daiwa Securities
Guggenheim
Argus
Deutsche Bank Securities
TD Cowen
Leerink Partners
Citigroup
Cantor Fitzgerald
RBC Capital Markets
Morgan Stanley
Goldman Sachs
Oppenheimer
UBS
Bernstein
Wells Fargo Securities
HSBC
BMO Capital
Piper Sandler
Scotiabank
DZ Bank
DBS Bank
Rothschild & Co Redburn
BofA Securities
Truist Securities
Jefferies & Co.
Redburn Atlantic
JPMorgan Chase
Barclays
William Blair & Co.
Baird
Credit Suisse
DA Davidson
SVB Securities LLC
Cowen
Atlantic Equities
SVB Leerink
JPMORGAN	Cory Kasimov
RBC	Kennen Mackay